Loading...

We've got a brand new version of Simply Wall St! Try it out

Vinergy Cannabis Capital

CNSX:VIN
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VIN
CNSX
CA$6M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Vinergy Cannabis Capital Inc. develops cannabis products using pharmaceutical formulation techniques to produce dosage forms for human use. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • Vinergy Cannabis Capital has significant price volatility in the past 3 months.
VIN Share Price and Events
7 Day Returns
-12%
CNSX:VIN
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:VIN
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
VIN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vinergy Cannabis Capital (VIN) -12% -38.9% - - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on VIN.
  • No trading data on VIN.
Price Volatility
VIN
Industry
5yr Volatility vs Market

VIN Value

 Is Vinergy Cannabis Capital undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vinergy Cannabis Capital. This is due to cash flow or dividend data being unavailable. The share price is CA$0.11.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vinergy Cannabis Capital's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vinergy Cannabis Capital's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:VIN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-05-31) in CAD CA$-0.03
CNSX:VIN Share Price ** CNSX (2019-09-20) in CAD CA$0.11
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vinergy Cannabis Capital.

CNSX:VIN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:VIN Share Price ÷ EPS (both in CAD)

= 0.11 ÷ -0.03

-4.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vinergy Cannabis Capital is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Vinergy Cannabis Capital is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Vinergy Cannabis Capital's expected growth come at a high price?
Raw Data
CNSX:VIN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vinergy Cannabis Capital, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vinergy Cannabis Capital's assets?
Raw Data
CNSX:VIN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-05-31) in CAD CA$0.02
CNSX:VIN Share Price * CNSX (2019-09-20) in CAD CA$0.11
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:VIN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:VIN Share Price ÷ Book Value per Share (both in CAD)

= 0.11 ÷ 0.02

5.75x

* Primary Listing of Vinergy Cannabis Capital.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vinergy Cannabis Capital is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Vinergy Cannabis Capital's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Vinergy Cannabis Capital has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

VIN Future Performance

 How is Vinergy Cannabis Capital expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vinergy Cannabis Capital has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vinergy Cannabis Capital expected to grow at an attractive rate?
  • Unable to compare Vinergy Cannabis Capital's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Vinergy Cannabis Capital's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Vinergy Cannabis Capital's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:VIN Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:VIN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:VIN Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-05-31 0 -1
2019-02-28 0 -1
2018-11-30 0 0
2018-08-31 0 0
2018-05-31 0 0
2018-02-28 0 0
2017-11-30 0 0
2017-08-31 0 0
2017-05-31 0 0
2017-02-28 0 0
2016-11-30 0 0
2016-08-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Vinergy Cannabis Capital is high growth as no earnings estimate data is available.
  • Unable to determine if Vinergy Cannabis Capital is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:VIN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Vinergy Cannabis Capital Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VIN Past Financials Data
Date (Data in CAD Millions) EPS *
2019-05-31 -0.03
2019-02-28 -0.03
2018-11-30 -0.01
2018-08-31 -0.01
2018-05-31 -0.01
2018-02-28 -0.01
2017-11-30 -0.01
2017-08-31 -0.01
2017-05-31 -0.01
2017-02-28 -0.01
2016-11-30 0.00
2016-08-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vinergy Cannabis Capital will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Vinergy Cannabis Capital's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Vinergy Cannabis Capital's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Vinergy Cannabis Capital's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Vinergy Cannabis Capital's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vinergy Cannabis Capital has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

VIN Past Performance

  How has Vinergy Cannabis Capital performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vinergy Cannabis Capital's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vinergy Cannabis Capital does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Vinergy Cannabis Capital's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vinergy Cannabis Capital's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Vinergy Cannabis Capital's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vinergy Cannabis Capital Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VIN Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-05-31 -1.24 0.12
2019-02-28 -1.24 0.11
2018-11-30 -0.21 0.10
2018-08-31 -0.22 0.10
2018-05-31 -0.26 0.11
2018-02-28 -0.27 0.12
2017-11-30 -0.33 0.14
2017-08-31 -0.33 0.15
2017-05-31 -0.27 0.10
2017-02-28 -0.27 0.10
2016-11-30 -0.09 0.05
2016-08-31 -0.10 0.05
2016-05-31 -0.10 0.05
2016-02-29 -0.10 0.06
2015-11-30 -0.10 0.06
2015-08-31 -0.13 0.08
2015-05-31 -0.14 0.08
2015-02-28 -0.15 0.08
2014-11-30 -0.20 0.10
2014-08-31 -0.17 0.08
2014-05-31 -0.17 0.09
2014-02-28 -0.16 0.09
2013-11-30 -0.10 0.09
2013-08-31 -0.11 0.09
2013-05-31 -0.09 0.06
2013-02-28 -0.10 0.06
2012-11-30 -0.17 0.05

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vinergy Cannabis Capital has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vinergy Cannabis Capital has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vinergy Cannabis Capital improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vinergy Cannabis Capital's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vinergy Cannabis Capital has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

VIN Health

 How is Vinergy Cannabis Capital's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vinergy Cannabis Capital's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vinergy Cannabis Capital is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vinergy Cannabis Capital has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vinergy Cannabis Capital's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 8.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vinergy Cannabis Capital Company Filings, last reported 3 months ago.

CNSX:VIN Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-05-31 0.95 0.24 0.13
2019-02-28 -0.27 0.24 0.04
2018-11-30 0.60 0.24 0.12
2018-08-31 0.61 0.24 0.71
2018-05-31 0.66 0.24 0.77
2018-02-28 0.67 0.24 0.83
2017-11-30 0.77 0.24 0.83
2017-08-31 0.79 0.24 1.06
2017-05-31 0.88 0.24 1.21
2017-02-28 0.90 0.26 1.58
2016-11-30 -0.86 0.24 0.00
2016-08-31 -0.84 0.24 0.00
2016-05-31 -0.81 0.24 0.00
2016-02-29 -0.79 0.24 0.00
2015-11-30 -0.77 0.26 0.00
2015-08-31 -0.74 0.26 0.00
2015-05-31 -0.71 0.26 0.00
2015-02-28 -0.69 0.26 0.00
2014-11-30 -0.66 0.26 0.00
2014-08-31 -0.61 0.25 0.00
2014-05-31 -0.57 0.24 0.03
2014-02-28 -0.54 0.24 0.04
2013-11-30 -0.47 0.18 0.12
2013-08-31 -0.56 0.18 0.00
2013-05-31 -0.52 0.18 0.01
2013-02-28 -0.49 0.16 0.00
2012-11-30 -0.48 0.16 0.01
  • Vinergy Cannabis Capital's level of debt (24.8%) compared to net worth is satisfactory (less than 40%).
  • Vinergy Cannabis Capital had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vinergy Cannabis Capital has sufficient cash runway for 1.5 years based on current free cash flow.
  • Vinergy Cannabis Capital has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 23.4% each year.
X
Financial health checks
We assess Vinergy Cannabis Capital's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vinergy Cannabis Capital has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

VIN Dividends

 What is Vinergy Cannabis Capital's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vinergy Cannabis Capital dividends.
If you bought CA$2,000 of Vinergy Cannabis Capital shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vinergy Cannabis Capital's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vinergy Cannabis Capital's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:VIN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vinergy Cannabis Capital has not reported any payouts.
  • Unable to verify if Vinergy Cannabis Capital's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vinergy Cannabis Capital's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vinergy Cannabis Capital has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vinergy Cannabis Capital's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vinergy Cannabis Capital afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vinergy Cannabis Capital has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

VIN Management

 What is the CEO of Vinergy Cannabis Capital's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Glen MacDonald
COMPENSATION CA$0
AGE 68
TENURE AS CEO 2.8 years
CEO Bio

Dr. Glen C. MacDonald, Ph.D., serves as Director of Klondike Silver Corporation since December 12, 2018. He has been the Chief Executive Officer, President and Company Secretary of Vinergy Cannabis Capital Inc. since December 12, 2016 and its Chief Financial Officer since January 30, 2019. He is a Professional Geologist since 1982. Dr. MacDonald serves as Chief Executive Officer, President and Chief Financial Officer of Wayzata Finance Inc. He serves as Chief Technology Officer at Eleven Biotherapeutics, Inc. Dr. MacDonald served as the Chief Scientific Officer of Eleven Biotherapeutics, Inc. since September 20, 2016. He has been the Chief Financial Officer at ACGT DNA Technologies Corporation since January 2014. He served as the Chief Executive Officer of ACGT DNA Technologies Corporation since April 15, 2015 until December 12, 2016. He serves as a Senior Research Executive in Viventia and is responsible for its overall research and operational activities at its Winnipeg facility. Dr. MacDonald served as the Chief Scientific Officer of Viventia Biotechnologies Inc. since 2012 and served as its Vice President of Operations since January 2004. He served as the Chief Executive Officer, Chief Financial Officer and Secretary of Leucadia Finance Partners Inc., since January 12, 2014 until June 3, 2014. He served as the President, Chief Executive Officer and Chief Financial Officer at Leucadia Finance Partners Inc. until August 31, 2017. He joined Viventia Biotech in July 1997 and served positions of increasing responsibility within it becoming the Vice President of Research in 2004. Prior to joining Viventia Biotech, Dr. MacDonald was associated with The University of Manitoba Cancer Treatment Research Foundation, The University of North Carolina, Chapel Hill and the Ontario Cancer Institute, Princess Margaret Hospital. Mr. MacDonald has extensive experience with public companies as a Director and a wide variety of Officer Positions. He served as an Independent Director of Yorkton Ventures Inc. since December 14, 2012. He has been a Director at 0990756 B.C. Ltd. since June 2014. He has been a Director of ACGT DNA Technologies Corporation and Wayzata Finance Inc. since January 12, 2014. He has been a Director of Vanguard Investments Corp. since November 30, 2009, AVC Venture Corp. since November 1999, Dunes Exploration Ltd. (formerly Dynamic Resources Corp.) since September 1993 and Maxim Resources Inc. since May 2002. He has been a Director of Vinergy Cannabis Capital Inc. since November 30, 2009. He served as a Director of Corniche Capital Ltd. until August 4, 1999 and Printlux.com until August 2001. He served as a Director of Leucadia Finance Partners Inc since January 12, 2014 until August 31, 2017. He has published in the areas of monoclonal antibodies, graft-versus-host disease, lupus and apoptosis. Dr. MacDonald graduated from the University of Guelph with a Bachelor’s Degree in Genetics in 1980 and earned a M.Sc. and a Ph.D. in immunology from the University of Manitoba in 1987 and 1993, respectively.

CEO Compensation
  • Insufficient data for Glen to compare compensation growth.
  • Insufficient data for Glen to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Glen MacDonald

TITLE
CEO, CFO
AGE
68
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the Vinergy Cannabis Capital board of directors in years:

3
Average Tenure
68
Average Age
  • The tenure for the Vinergy Cannabis Capital board of directors is about average.
Board of Directors

Glen MacDonald

TITLE
CEO, CFO
AGE
68
TENURE
9.8 yrs

Will Panenka

TITLE
Chairman of Scientific Advisory Board
TENURE
2.7 yrs

Ken Ralfs

TITLE
Director
AGE
72
TENURE
5.8 yrs

Glen Indra

TITLE
Director
TENURE
3.4 yrs

John Simon

TITLE
Member of Scientific Advisory Board
TENURE
2.6 yrs

Eugene Beukman

TITLE
Director
AGE
61
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Vinergy Cannabis Capital's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vinergy Cannabis Capital has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

VIN News

Simply Wall St News

We Think Vinergy Cannabis Capital (CNSX:VIN) Has A Fair Chunk Of Debt

As you can see below, Vinergy Cannabis Capital had CA$235.0k of debt, at February 2019, which is about the same the year before. … CNSX:VIN Historical Debt, August 1st 2019 How Healthy Is Vinergy Cannabis Capital's Balance Sheet? … Zooming in on the latest balance sheet data, we can see that Vinergy Cannabis Capital had liabilities of CA$1.14m due within 12 months and no liabilities due beyond that.

Simply Wall St -

VIN Company Info

Description

Vinergy Cannabis Capital Inc. develops cannabis products using pharmaceutical formulation techniques to produce dosage forms for human use. Its brands include Phytocine and Rehab Rx, which are manufactured from proprietary strains of whole plant hemp extracts, containing a spectrum of phytocannabinoids, including CBD, terpenes, flavonoids, and other hemp compounds. It also develops and invests in proprietary genetics and formulation for development and delivery systems of nutraceutical products, as well as the development of hemp derived consumer products. The company was formerly known as Vinergy Resources Ltd. and changed its name to Vinergy Cannabis Capital Inc. in July 2019. Vinergy Cannabis Capital Inc. is headquartered in Vancouver, Canada.

Details
Name: Vinergy Cannabis Capital Inc.
VIN
Exchange: CNSX
Founded:
CA$6,292,659
57,205,994
Website: http://www.phytopharma.ca
Address: Vinergy Cannabis Capital Inc.
409 Granville Street,
Suite 1008,
Vancouver,
British Columbia, V6C 1T2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX VIN Voting Common Shares Canadian National Stock Exchange CA CAD 23. Oct 2015
OTCPK VNNY.F Voting Common Shares Pink Sheets LLC US USD 23. Oct 2015
DB 1V7 Voting Common Shares Deutsche Boerse AG DE EUR 23. Oct 2015
Number of employees
Current staff
Staff numbers
0
Vinergy Cannabis Capital employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:37
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/30
Last earnings reported: 2019/05/31
Last annual earnings reported: 2019/02/28


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.